Danaher Corporation

NYSE:DHR 株式レポート

時価総額：US$121.7b

Danaher 過去の業績

過去 基準チェック /16

Danaherの収益は年間平均-11.3%の割合で減少していますが、 Life Sciences業界の収益は年間 減少しています。収益は年間3.8% 3.5%割合で 減少しています。 Danaherの自己資本利益率は6.9%であり、純利益率は14.8%です。

主要情報

-11.32%

収益成長率

-11.60%

EPS成長率

Life Sciences 業界の成長21.51%
収益成長率-3.48%
株主資本利益率6.94%
ネット・マージン14.83%
前回の決算情報27 Mar 2026

最近の業績更新

Recent updates

ナラティブの更新 • May 19

DHR: Bioprocess Recovery And Masimo Deal Set To Support Premium Multiple

Analysts have trimmed the implied fair value for Danaher by about $2 to roughly $248 per share, as they balance slightly higher long term growth and margin expectations with a lower assumed P/E multiple, evolving views on bioprocess recovery, and recent price target changes across the Street. Analyst Commentary Recent Street commentary around Danaher reflects a mixed but engaged view, with several firms adjusting price targets and reassessing how quickly the company can execute on its bioprocess ambitions and broader portfolio moves.
ナラティブの更新 • May 02

DHR: Masimo Cash Acquisition Will Support Premium Future Earnings Multiple

Danaher’s updated analyst price target moves lower by about $8 per share to roughly $250, as analysts factor in more conservative assumptions for growth, profitability and future P/E multiples following a recent series of mostly downward target revisions across the Street. Analyst Commentary Recent research on Danaher reflects a mixed but generally cautious tone, with several price target cuts offset by one modest increase and a change in rating context at another company linked to Danaher’s pending acquisition activity.
Seeking Alpha • Apr 22

Danaher Q1 2026 Earnings Update

Summary Danaher had another somewhat uneventful quarter. Margin in biotechnology segment improved YoY to reach 42.7% in 1Q’26. Life Sciences segment’s core revenue grew at only 0.5% despite having an easy comp of -4% in 1Q’25. Management kept their core revenue guidance of ~3-6% but raised the high end of 2026 EPS guidance from $8.5 to $8.55. Read the full article on Seeking Alpha
新しいナラティブ • Apr 20

Danaher Corporation (DHR): The Life Sciences Titan and the "Diagnostic Diversification" Shift

Danaher Corporation (DHR) , the global life sciences and diagnostics innovator, enters Tuesday, April 21, 2026 , following a mixed but resilient first-quarter earnings performance. Trading at $195.60 USD —a marginal 0.05% gain in a volatile post-earnings session—the stock is seeking firm support above its recent low of $181.01.
ナラティブの更新 • Apr 16

DHR: Masimo Cash Deal Will Support Premium Future Earnings Multiple

Danaher’s analyst price target has been reset from about $264.91 to $257.73, as analysts factor in updated assumptions around profit margins, revenue growth, discount rates and future P/E, alongside mixed recent research that includes both target raises and cuts, as well as the planned Masimo acquisition. Analyst Commentary Recent research on Danaher reflects a split view, with some firms raising their price targets and others trimming them, while the planned Masimo acquisition sits at the center of many discussions about valuation and execution risk.
ナラティブの更新 • Apr 01

DHR: Cash Deal For Masimo Will Support Premium Future Earnings Multiple

Analysts have nudged Danaher’s price targets higher by low double digit dollar amounts, pointing to updated views on discount rates, revenue growth, profit margins and future P/E assumptions as the key drivers behind the revised dollar values. Analyst Commentary Recent research has focused on how Danaher’s valuation reflects expectations for future execution, especially in light of the planned Masimo acquisition and refreshed targets across the life science tools peer group.
ナラティブの更新 • Mar 18

DHR: Cash Acquisition Will Support Re Rating And Premium Earnings Multiple

Analysts have nudged their price targets on Danaher higher by a few dollars into the mid $260s, citing a series of upward target revisions across the Street and support from the announced Masimo acquisition at $180 per share in cash. Analyst Commentary Recent research around Danaher has centered on the Masimo acquisition agreement at $180 per share in cash and a cluster of higher price targets that place the stock in the mid $260s to around $270.
ナラティブの更新 • Mar 04

DHR: Masimo Cash Deal Will Support Re Rating And Premium Multiple

The analyst price target for Danaher has moved higher by a mid single digit dollar amount, reflecting updated assumptions for slightly stronger revenue growth and margins, alongside recent Street research that raised targets following the Masimo acquisition announcement and sector wide target adjustments. Analyst Commentary Recent Street research around Danaher reflects a mix of optimism on the Masimo acquisition and valuation, alongside a more cautious stance on deal terms and execution risk.
ナラティブの更新 • Feb 17

DHR: Masimo Deal And Higher Future P/E Will Support Premium Multiple

Danaher’s updated analyst price target edges slightly lower to about $265, as analysts balance modest tweaks to revenue growth, profit margin and P/E assumptions with a broadly supportive run of recent target increases across the Street. Analyst Commentary Recent Street research on Danaher is clustered around higher price targets, with several bullish analysts lifting their numbers by single digit to low double digit dollar amounts.
ナラティブの更新 • Feb 03

DHR: Higher Future P/E Assumptions Will Support Premium Multiple Through Soft 2026 Outlook

Analysts have nudged their average price target for Danaher higher, with our fair value estimate moving from US$261.50 to about US$265.23. This change is supported by a modestly higher assumed future P/E multiple and by Street research that has generally lifted targets in the life science tools sector.
ナラティブの更新 • Jan 19

DHR: Share Repurchases And Soft 2026 Outlook Will Support Premium Multiple

Analysts have nudged their price targets on Danaher higher, reflected in a fair value update from US$259.23 to US$261.50, citing refreshed views on revenue growth, profit margins, and future P/E expectations in recent research. Analyst Commentary Recent price target moves on Danaher point to refreshed views on how the company could execute on growth plans, manage profitability, and justify its current P/E profile.
ナラティブの更新 • Jan 05

DHR: Share Repurchases And Diagnostics Resilience Will Support Premium Multiple

Analysts have made a modest upward adjustment to their fair value estimate for Danaher to about US$259 from about US$258, reflecting slightly higher assumed profit margins and P/E, even as they highlight tempered expectations for 2025 and 2026 growth, ongoing uncertainty in China, and questions around how durable diagnostics demand will be. Analyst Commentary Analysts are split on Danaher, with some focusing on the valuation premium and others on the company’s ability to eventually reconnect with its historical growth profile.
ナラティブの更新 • Dec 19

DHR: Share Repurchases Will Support Premium Multiple As Life Sciences Demand Recovers

Analysts modestly raised their blended fair value estimate for Danaher to about $258 from roughly $256, reflecting slightly lower discount rate and higher future multiple assumptions, even as they trim official price targets toward $220 amid ongoing uncertainty around the pace of life sciences and diagnostics recovery. Analyst Commentary Analysts broadly agree that Danaher's premium valuation assumes a reacceleration of growth across life sciences and diagnostics, but they remain divided on how quickly fundamentals will normalize versus the lingering headwinds in key end markets.
ナラティブの更新 • Dec 04

DHR: Share Repurchases Will Support Premium Multiple Despite Slower Recovery Uncertainty

Danaher's fair value estimate has been nudged slightly higher to approximately $255.67 from about $254.20, as analysts balance still premium valuations and tempered growth expectations with signs of stabilization in key Life Sciences and Diagnostics markets. Analyst Commentary Recent Street research reflects a more balanced, wait and see stance on Danaher as investors weigh premium valuation levels against a slower growth trajectory and a gradual recovery in key end markets.
ナラティブの更新 • Nov 20

DHR: Share Repurchases And Improving Profit Margins Will Drive Renewed Upside

Danaher's fair value estimate has edged slightly lower to $254.20 from $254.40, as analysts cite ongoing uncertainty in growth outlooks and mixed sector momentum. Analyst Commentary Recent analyst reports on Danaher reveal a mix of optimism around the company’s long-term positioning and concerns about near-term growth visibility and sector headwinds.
ナラティブの更新 • Nov 04

DHR: Premium Outlook Will Be Sustained As Market Recovery Gradually Unfolds

Danaher’s fair value estimate has increased to $254.40 from $247.30. This reflects analysts’ view that while growth forecasts are now more gradual and discount rates slightly higher, the stock’s premium valuation still prices in a slow recovery and ongoing sector uncertainties.
ナラティブの更新 • Oct 21

Analyst Commentary Highlights Mixed Sentiment and Minor Valuation Adjustments for Danaher

Analysts have marginally raised their fair value estimate for Danaher to $247.30 from $244.50, citing improved profit margins and earnings quality. However, near-term growth expectations remain tempered by ongoing market uncertainties.
ナラティブの更新 • Sep 11

Advanced Diagnostics And Personalized Therapies Will Expand Global Markets

Danaher’s consensus price target saw a marginal downward revision to $244.50 as analysts incorporate more conservative near-term estimates amid continued sector weakness and tempered recovery expectations, despite steady long-term fundamentals. Analyst Commentary Bearish analysts are lowering price targets due to "more realistic" multiples and sector-wide weakness in Life Sciences Tools and Diagnostics, with a cautious view on near-term healthcare stock performance.
分析記事 • Aug 01

Some May Be Optimistic About Danaher's (NYSE:DHR) Earnings

Danaher Corporation's ( NYSE:DHR ) recent soft profit numbers didn't appear to worry shareholders, as the stock price...
分析記事 • Jul 12

Is Danaher Corporation (NYSE:DHR) Trading At A 33% Discount?

Key Insights Danaher's estimated fair value is US$304 based on 2 Stage Free Cash Flow to Equity Current share price of...
Seeking Alpha • Mar 31

Danaher: Some Near-Term Headwinds, But Good Long-Term Prospects And Low Valuations

Summary Danaher is well-positioned for revenue growth, driven by strong Biotechnology orders, Chinese stimulus in Life Sciences, and innovative products in Diagnostics despite near-term headwinds. Margins face short-term pressure from China's VBP initiative, but cost-cutting measures and operational efficiency should drive long-term margin expansion. The stock is undervalued compared to historical levels, trading at a discount to its average forward P/E over the last five years. I maintain a buy rating on DHR stock due to its strong long-term growth prospects and attractive valuation. Read the full article on Seeking Alpha
Seeking Alpha • Mar 22

Danaher: Near 5-Year Low Is A Great Entry Point

Summary Danaher Corporation is trading near its 5-year low, presenting a potential buying opportunity for growth investors despite near-term headwinds. DHR's strong fundamentals include leadership in biotechnology, life sciences, and diagnostics, with robust profitability and free cash flow. Growth catalysts include advancements in bioprocessing, molecular diagnostics, and neurodegenerative disease detection, with expected EPS growth of 10%-13% annually over the next three years. Read the full article on Seeking Alpha
Seeking Alpha • Feb 17

Danaher: Self-Inflicted Pessimism?

Summary Danaher Corp. has faced market punishment recently, but maintains strong margins and impressive FCF despite a tough year, indicating resilience and potential for future growth. The company’s strategic capital allocation, including share buybacks and acquisitions, suggests management is positioning for long-term value creation, despite short-term pessimism. Danaher’s bioprocessing segment shows consistent growth, and the upcoming patent cliff is expected to provide significant tailwinds, boosting demand for their life science equipment. Valuation analysis indicates the stock is currently undervalued, with potential for significant upside as market conditions improve and growth returns, making it a buy. Read the full article on Seeking Alpha
Seeking Alpha • Jan 15

Danaher Corporation: Question Mark Behind The Moat And Probably Overvalued

Summary Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles, Danaher has strong growth potential driven by secular tailwinds like an aging population and technological advancements in diagnostics. The company exhibits a wide economic moat due to high switching costs and stable margins, but its RoIC is below the ideal threshold. Currently, Danaher is overvalued with high P/E and P/FCF ratios, making it a "Hold" rather than a buy, pending future performance improvements. Read the full article on Seeking Alpha
Seeking Alpha • Jan 06

Danaher: A Wide-Moat Gem I Cannot Buy Enough Of

Summary Danaher boasts a wide-moat business model with mission-critical products and recurring revenue streams, ensuring a durable competitive advantage and long-term growth potential. The company's disciplined M&A strategy and integration capabilities have driven significant value creation, supported by strong secular healthcare trends and a focus on innovation. Despite a modest 0.5% dividend yield, Danaher's 12.4% five-year CAGR and low payout ratio offer substantial growth potential for total return investors. Trading at a reasonable valuation, Danaher is poised for a rebound with expected double-digit EPS growth, making it an excellent choice for long-term accumulation. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Danaher: A Resilient And Solid Company With Growth Potential

Summary Danaher has maintained a net earning margin above 15% since 2017. In 2024 Q3, the company had a 36.36% liabilities-to-assets ratio, the lowest level since 2017. Danaher's largest customers have reduced their excess of COVID-19-related products. So, Danaher expects a further boost in its sales. The company has been successful in generating growth through acquiring other companies. In the last ten years, half of Danaher's growth has come due to this strategy. Read the full article on Seeking Alpha
Seeking Alpha • Oct 25

Understanding Danaher's Cautiousness

Summary Danaher reported okay Q3 earnings, with "cautiousness" probably being the best adjective to describe the release. The company has finally returned to growth and forward-looking commentary seems positive, but management seems reluctant to put numbers around their optimism. There might be a reason behind the conservativeness, which I explain in this article. Read the full article on Seeking Alpha

収支内訳

Danaher の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NYSE:DHR 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
27 Mar 2624,7783,6757,5591,606
31 Dec 2524,5683,6007,5761,598
26 Sep 2524,2683,5037,6501,602
27 Jun 2524,0133,4137,6001,607
28 Mar 2523,8203,7657,5001,595
31 Dec 2423,8753,8997,4501,584
27 Sep 2423,7423,9347,4701,549
28 Jun 2423,5684,0567,3581,528
29 Mar 2423,7374,0697,2811,498
31 Dec 2323,8904,2007,2451,503
29 Sep 2321,0264,4086,0801,332
30 Jun 2323,0655,0196,4891,390
31 Mar 2324,9045,7576,7621,460
31 Dec 2226,6436,2227,0801,528
30 Sep 2231,2506,6408,5721,787
01 Jul 2230,8166,2068,4891,808
01 Apr 2230,2836,2068,3691,803
31 Dec 2124,8025,2836,7631,498
01 Oct 2128,0655,6367,8181,643
02 Jul 2126,7205,3617,5431,544
02 Apr 2124,7994,5957,2781,441
31 Dec 2022,2843,5106,8801,348
02 Oct 2020,3923,0836,3541,246
03 Jul 2018,8862,8535,9541,186
03 Apr 2018,0342,6145,6591,146
31 Dec 1917,9112,3645,5771,126
27 Sep 1915,5622,0934,709980
28 Jun 1916,0372,1454,880998
29 Mar 1916,5732,1665,1251,028
31 Dec 1817,0492,4065,3561,059
28 Sep 1819,6152,7616,2461,211
29 Jun 1819,2902,6696,1731,189
30 Mar 1818,8192,5536,0721,160
31 Dec 1715,5192,1725,012956
29 Sep 1717,8282,3605,7641,098
30 Jun 1717,4322,1915,6331,060
31 Mar 1717,1642,0515,5361,016
31 Dec 1616,8822,1535,481975
30 Sep 1616,6211,9275,362943
01 Jul 1616,0011,9055,218914
01 Apr 1613,6631,7754,549788
31 Dec 1514,4341,7474,635861
02 Oct 1515,3351,8754,769926
03 Jul 1516,5302,1774,8651,002

質の高い収益: DHRは 高品質の収益 を持っています。

利益率の向上: DHRの現在の純利益率 (14.8%)は、昨年(15.8%)よりも低くなっています。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: DHRの収益は過去 5 年間で年間11.3%減少しました。

成長の加速: DHRは過去 1 年間の収益成長がマイナスであったため、5 年間の平均と比較することはできません。

収益対業界: DHRは過去 1 年間で収益成長率がマイナス ( -2.4% ) となったため、 Life Sciences業界平均 ( 3.8% ) と比較することが困難です。

株主資本利益率

高いROE: DHRの 自己資本利益率 ( 6.9% ) は 低い とみなされます。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/26 13:23
終値2026/05/26 00:00
収益2026/03/27
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Danaher Corporation 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。44

アナリスト機関
John EadeArgus Research Company
Catherine Ramsey SchulteBaird
Luke SergottBarclays